1413 related articles for article (PubMed ID: 30179153)
1. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Flaherty K; Havard D; Heptinstall S; James M; Krishnan K; Markus HS; Montgomery AA; Pocock SJ; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N;
Lancet; 2018 Mar; 391(10123):850-859. PubMed ID: 29274727
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388).
; Krishnan K; Beridze M; Christensen H; Dineen R; Duley L; Heptinstall S; James M; Markus HS; Pocock S; Ranta A; Robinson T; Nikola N; Venables G; Bath P
Int J Stroke; 2015 Oct; 10(7):1159-65. PubMed ID: 26079743
[TBL] [Abstract][Full Text] [Related]
4. Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Woodhouse LJ; Appleton JP; Christensen H; Dineen RA; England TJ; James M; Krishnan K; Montgomery AA; Ranta A; Robinson TG; Sprigg N; Bath PM
Sci Rep; 2023 Jul; 13(1):11717. PubMed ID: 37474599
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Bath PM; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Heptinstall S; James M; Krishnan K; Markus HS; Pocock S; Ranta A; Robinson TG; Flaherty K; Scutt P; Venables GS; Woodhouse LJ; Sprigg N
Int J Stroke; 2017 Jul; 12(5):524-538. PubMed ID: 27811309
[TBL] [Abstract][Full Text] [Related]
6. Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
Bath PM; Robson K; Woodhouse LJ; Sprigg N; Dineen R; Pocock S;
Int J Stroke; 2015 Apr; 10(3):449-51. PubMed ID: 25640807
[TBL] [Abstract][Full Text] [Related]
7. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
Hao Q; Tampi M; O'Donnell M; Foroutan F; Siemieniuk RA; Guyatt G
BMJ; 2018 Dec; 363():k5108. PubMed ID: 30563866
[TBL] [Abstract][Full Text] [Related]
10. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.
Dengler R; Diener HC; Schwartz A; Grond M; Schumacher H; Machnig T; Eschenfelder CC; Leonard J; Weissenborn K; Kastrup A; Haberl R;
Lancet Neurol; 2010 Feb; 9(2):159-66. PubMed ID: 20060783
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Hankey GJ
Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel with indobufen or aspirin in minor ischemic stroke or high-risk transient ischemic attack: a randomized controlled clinical study.
Liu X; Lv X; Peng Y; Wang J; Lei J; Tang C; Luo S; Mai W; Cai Y; Fan Q; Liu C; Zhang L
BMC Neurol; 2024 Mar; 24(1):81. PubMed ID: 38429754
[TBL] [Abstract][Full Text] [Related]
13. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
[TBL] [Abstract][Full Text] [Related]
14. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
17. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
Rothwell PM; Algra A; Chen Z; Diener HC; Norrving B; Mehta Z
Lancet; 2016 Jul; 388(10042):365-375. PubMed ID: 27209146
[TBL] [Abstract][Full Text] [Related]
18. Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Zhang XG; Zhu XQ; Xue J; Li ZZ; Jiang HY; Hu L; Yue YH
BMJ Open; 2019 May; 9(5):e028595. PubMed ID: 31123001
[TBL] [Abstract][Full Text] [Related]
19. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack.
Naqvi IA; Kamal AK; Rehman H
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD009716. PubMed ID: 32813275
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES).
Gao Y; Pan Y; Han S; Chen W; Jing J; Wang C; Yang Y; Wang T; Meng X; Zhao X; Liu L; Li H; Johnston SC; Amarenco P; Bath PM; Wang Y; Wang Y;
Stroke Vasc Neurol; 2023 Jun; 8(3):249-258. PubMed ID: 36707080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
